Associated Papers
Molecular Characterization of Advanced-Stage Melanomas in Clinical Practice Using a Laboratory-Developed Next-Generation Sequencing Panel.
Maloberti T et al.
Diagnostics (basel, Switzerland), 2024
38667446 (PubMed )
Supplement: diagnostics-14-00800-s001.zip › Supplementary_Table_S1.xlsx › Foglio1
Clinical, Pathological and Molecular Insights on KRAS, NRAS, BRAF, PIK3CA and TP53 Mutations in Metastatic Colorectal Cancer Patients from Northeastern Romania.
Afrăsânie VA et al.
International Journal of Molecular Sciences, 2023
Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential.
Voutsadakis IA
Medicina (kaunas, Lithuania), 2022
Somatic targeted mutation profiling of colorectal cancer precursor lesions.
Dos Santos W et al.
Bmc Medical Genomics, 2022
35761395 (PubMed )
Supplement: 12920_2022_1294_MOESM5_ESM.xlsx › Table_S2
BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.
Miele E et al.
Bmc Cancer, 2020
Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer.
Duplaquet L et al.
Molecular Cancer Therapeutics, 2019
Comprehensive identification of long noncoding RNAs in colorectal cancer.
James de Bony E et al.
Oncotarget, 2018
29963224 (PubMed )
Supplement: oncotarget-09-27605-s005.xlsx › Sheet1
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment.
Martinelli E et al.
Esmo Open, 2017
29211816 (PubMed )
Supplement: esmoopen-2017-000177supp001.pdf
Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
Løes IM et al.
International Journal of Cancer, 2016
26991344 (PubMed )
Supplement: IJC-139-647-s003.xls › Suppl_Tbl_2
Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
Hsu HC et al.
Oncotarget, 2016
26989027 (PubMed )
Supplement: oncotarget-07-22257-s001.pdf
Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.
Birch AH et al.
Plos One, 2011
DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.
Berg M et al.
Plos One, 2010
21103049 (PubMed )
Supplement: pone.0013978.s002.xls › Table_S2
High resolution melting for mutation scanning of TP53 exons 5-8.
Krypuy M et al.
Bmc Cancer, 2007
Circulating Tumor DNA Testing Overcomes Limitations of Comprehensive Genomic Profiling from Tumor Tissue.
Kumar A et al.
Case Reports in Oncology, 0
Select a paper to view details